TheraCoat is a clinical stage specialty pharmaceutical company focused on innovative sustained release formulations for the treatment of urinary tract diseases.
TheraCoat technology enables control on the pharmacokinetics of drugs resulting in an optimized Therapeutic Index without changing the drug molecular structure.
TheraCoat sustained release technology enables controlled and longer exposure of bladder tissue to medications (such as chemotherapy) as compared to standard intravesical instillations.
TheraCoat core capabilities are based on using a family of proprietary reverse thermal-gelation hydrogels that have ideal properties for deployment of medications into the urinary tract.
TheraCoat has been granted CE Mark clearance as a Medical Device.
Recently, TheraCoat has been granted Orphan Drug Designation from the US FDA for its Innovative Treatment MitoGel™ (Mitomycin embedded in the hydrogel) for Upper Tract Urothelial Carcinoma.
TheraCoat is currently focused on local treatments for: non-muscle-invasive or superficial bladder cancer (NMIBC), upper tract urothelial carcinoma (UTUC), interstitial cystitis (IC) and overactive bladder (OAB) – treatments that together address millions of patients worldwide.